Arcutis Biotherapeutics, Inc (ARQT)

Etorro trading 970x250
Arcutis Biotherapeutics, Inc (ARQT) Logo

About Arcutis Biotherapeutics, Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California. Address: 3027 Townsgate Road, Westlake Village, CA, United States, 91361

Arcutis Biotherapeutics, Inc News and around…

Latest news about Arcutis Biotherapeutics, Inc (ARQT) common stock and company :

Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis
04 Oct, 2021 Yahoo! Finance

Plaque psoriasis is a skin disease that affects approximately 8.6 million individuals in the U.S. and presents particular treatment challenges in certain anatomical regions.Roflumilast cream, a non-steroidal treatment intended for chronic use, would be the first and only topical PDE4 inhibitor for psoriasis, if approved.Roflumilast cream demonstrated statistically significant superiority over vehicle on the primary endpoint of IGA Success and statistically significant improvements in multiple se

New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at European Academy of Dermatology and Venereology Congress
30 Sep, 2021 FinancialContent
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
30 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent
28 Sep, 2021 FinancialContent
Implied VTWG Analyst Target Price: $269
27 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Growth ETF (VTWG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $268.76 per unit.

New Topical Roflumilast Data Presented at the European Academy of Dermatology and Venereology (EADV) Congress
27 Sep, 2021 FinancialContent
Is Now the Time to Bet on Arcutis Biotherapeutics?
18 Sep, 2021 FinancialContent

Management has high hopes for the company's treatment candidates for dermatological conditions, but can they get one to market before its cash cushion is depleted?

Notable Wednesday Option Activity: ARQT, MU, PCTY
15 Sep, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Arcutis Biotherapeutics Inc (ARQT), where a total volume of 803 contracts has been traded thus far today, a contract volume which is representative of approximately 80,300 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 49.5% of ARQT's average daily trading volume over the past month, of 162,305 shares..

Arcutis to Present at Upcoming Investor Conferences
09 Sep, 2021 FinancialContent
Arcutis Announces Appointment of Keith Leonard to Board of Directors
02 Sep, 2021 FinancialContent
How The Parts Add Up: XBI Headed For $211
27 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $211.41 per unit.

Arcutis Enrolls First Patient in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Scalp and Body Psoriasis
25 Aug, 2021 FinancialContent
Bruce Binkowitz Joins Arcutis as Vice President of Biometrics
23 Aug, 2021 FinancialContent
Arcutis Announces Second Quarter 2021 Financial Results and Provides Business Update
05 Aug, 2021 FinancialContent
Arcutis Biotherapeutics Enters Oversold Territory (ARQT)
04 Aug, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Arcutis Announces Additions to its Investor Relations and Communications Team
02 Aug, 2021 FinancialContent
All You Need to Know About Arcutis Biotherapeutics, Inc. (ARQT) Rating Upgrade to Buy
23 Jul, 2021 Yahoo! Finance

Arcutis Biotherapeutics, Inc. (ARQT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Arcutis Advances Science of Psoriasis Drug Development with New Precision Method for Measuring Mild-to-Moderate Psoriasis
21 Jul, 2021 FinancialContent
Albireo (ALBO) Cholestasis Drug Bylvay Gets European Approval
20 Jul, 2021 Yahoo! Finance

Albireo's (ALBO) Bylvay becomes the first and only drug to treat progressive familial intrahepatic cholestasis, following its approval in Europe.

Psychedelic Science Leader Eleusis Announces Four New Board Appointments, Further Strengthening Leadership
12 Jul, 2021 FinancialContent

Eleusis, a life science company focused on psychedelic drug development and delivery, appoints four business leaders to its board of directors.

Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis
12 Jul, 2021 FinancialContent
Arcutis (ARQT) Terminates Study of Drug to Treat Vitiligo
02 Jul, 2021 Yahoo! Finance

Arcutis (ARQT) ends phase IIa study evaluating its investigational anti-JAK1 candidate, ARQ-252, to treat vitiligo.

Arcutis Stops ARQ-252 Vitiligo Trial After Formulation-Related Observations In Chronic Hand Eczema Study
01 Jul, 2021 FinancialContent

Arcutis Biotherapeutics Inc(NASDAQ: ARQT)will terminate the Phase 2a trialevaluating ARQ-252 as a potential ...

Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo
01 Jul, 2021 FinancialContent
Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2021
30 Jun, 2021 FinancialContent

Upgrades For Taiwan Semiconductor Manufacturing Co Ltd (NYSE:TSM), Susquehanna upgraded the previous rating of Negative to Neutral. For ...

Greg Sukay Joins Arcutis as Vice President of Manufacturing and Process Technologies
23 Jun, 2021 FinancialContent
How The Pieces Add Up: VHT Targets $272
22 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $272.01 per unit.

Notable Thursday Option Activity: ZEN, TWO, ARQT
17 Jun, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Zendesk Inc (ZEN), where a total volume of 5,472 contracts has been traded thus far today, a contract volume which is representative of approximately 547,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 70.9% of ZEN's average daily trading volume over the past month, of 771,775 shares..

Arcutis Announces Appointment of Sue-Jean Lin to Board of Directors
09 Jun, 2021 FinancialContent
Rajvir Madan Joins Arcutis as Chief Digital and Information Officer
01 Jun, 2021 FinancialContent

Arcutis Biotherapeutics, Inc (ARQT) is a NASDAQ Common Stock listed in , ,

970x250